KR870000426A - 합성 fmdv 백신용 화합물의 제조방법 - Google Patents

합성 fmdv 백신용 화합물의 제조방법 Download PDF

Info

Publication number
KR870000426A
KR870000426A KR1019860004336A KR860004336A KR870000426A KR 870000426 A KR870000426 A KR 870000426A KR 1019860004336 A KR1019860004336 A KR 1019860004336A KR 860004336 A KR860004336 A KR 860004336A KR 870000426 A KR870000426 A KR 870000426A
Authority
KR
South Korea
Prior art keywords
pro
cys
amino acid
sequence
formula
Prior art date
Application number
KR1019860004336A
Other languages
English (en)
Other versions
KR890003944B1 (ko
Inventor
데니스 디마치 리차드
스테펜 브룩 제랄드
Original Assignee
일라이 릴리 앤드 캄파니
메리 앤터커
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니, 메리 앤터커 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR870000426A publication Critical patent/KR870000426A/ko
Application granted granted Critical
Publication of KR890003944B1 publication Critical patent/KR890003944B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/222—Foot and mouth disease related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

합성 FMDV 백신용 화합물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 일반식(I)의 서열을 함유하는 상응하게 보호된 화합물로부터 보호그룹을 제거하거나,
    일반식(I)의 화합물을 코드화하는 DNA 서열을 함유하는 발현전이 벡터(expression transfer vector)에 의해 형질전환된 미생물을, 일반식(I)의 화합물을 코드화하는 DNA서열의 발현에 적절한 조건하에서 배양하고, 상기 미생물의 용균물(lysate) 또는 배양 배지로부터 일반식(I)화합물을 정제하고,
    경우에 따라, 유리 화합물을, 상응하는 약제학적으로 허용되는 염을 형성시키기 위해 염화(Safliying)시킴을 특징으로 하여, 일반식(I)의 서열을 함유하는 화합물 또는 그의 약제학적으로 허용되는 염을 제조하는 방법.
    X-A-Y-B-Z (I)
    상기 식에서,
    A및 B는 FMDV(foot-and-mouth disease virus) VP1 켑시드(Capsid) 단백질 혈청형(serotype)의 서열로 이루어진 아미노산 잔기 서열이며, 이들 중 하나는 18내지 24개의 아미노산 잔기를 함유하며 O혈청형의 141내지 158위치에 있는 아미노산 잔기 서열 또는 다른 혈청형의 동일한 서열을 포함하고, 이들 중 다른 하나는 14내지 20개의 아미노산 잔기를 함유하며 O혈청형의 200내지 213위치에 있는 아미노산 잔기 서열또는 다른 혈청형의 동일한 서열을 포함하며;
    X는 H, H-Cys 또는 H-Cys-Cys(이중에서 설프하이드릴은 차단되거나 유리될 수 있다)이고;
    Z는 OH, CyS-OH 또는 Pro-Cys-Gly-OH(이중에서 설프하이드릴은 차단되거나 유리될 수 있다)이며
    Y는 약 2내지 약 6개의 아미노산 잔기의 서열이다.
  2. 제1항에 있어서,
    X가 H-또는 H-CysCys-인 방법.
  3. 제1또는 2항에 있어서,
    Y가 2 내지 4개의 아미노산 잔기 서열인 방법.
  4. 제3항에 있어서,
    Y가 서열-Pro-Pro-를 함유하는 방법.
  5. 제4항에 있어서,
    Y가 -Pro-Pro-Ser- 또는 Leu-Pro-Pro-Thr인 방법.
  6. 제1내지 5항중 어느한 항에 있어서, Z가 -OH 또는 -Pro-Cys-Gly-OH인 방법.
  7. 제1항에 있어서,
    VP1(O1K)[Cys-Cys (200-213)-Pro-Pro-Ser(141-158)]-ProCysGly ; VP1(O1K)[200-213)-Pro-Pro-Ser-(141-158)]-ProCysGly ; 또는 그들의 약제학적으로 허용되는 염을 제조하는 방법.
  8. 제1항에 있어서,
    VP1(O1K) H-Cys-[ArgTyrAsnArgAsnAla(141-158)]-Leu ProProThr[GluAla(200-213)]-OH 또는 그의 약제학적으로 허용되는 염을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860004336A 1985-06-03 1986-06-02 합성 fmdv 백신용 화합물 KR890003944B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74078085A 1985-06-03 1985-06-03
US740780 1985-06-03

Publications (2)

Publication Number Publication Date
KR870000426A true KR870000426A (ko) 1987-02-18
KR890003944B1 KR890003944B1 (ko) 1989-10-13

Family

ID=24978033

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860004336A KR890003944B1 (ko) 1985-06-03 1986-06-02 합성 fmdv 백신용 화합물

Country Status (20)

Country Link
US (1) US4732971A (ko)
EP (1) EP0204480B1 (ko)
JP (1) JPS61282398A (ko)
KR (1) KR890003944B1 (ko)
CN (1) CN1019267B (ko)
AT (1) AT396248B (ko)
AU (1) AU595531B2 (ko)
DE (1) DE3686095T2 (ko)
DK (1) DK251286A (ko)
EG (1) EG17812A (ko)
ES (1) ES8707739A1 (ko)
GR (1) GR861406B (ko)
HK (1) HK101692A (ko)
HU (1) HUT41050A (ko)
IL (1) IL78913A (ko)
NZ (1) NZ216362A (ko)
PT (1) PT82651B (ko)
SG (1) SG94792G (ko)
SU (1) SU1662338A3 (ko)
ZA (1) ZA863911B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074650A (en) * 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5864008A (en) * 1988-03-25 1999-01-26 James; Stephen Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
CN1059347C (zh) * 1992-03-27 2000-12-13 牧岩生命工学研究所 制备肾病综合症出血热疫苗的方法
CN1054544C (zh) * 1993-10-21 2000-07-19 复旦大学 家畜口蹄疫病毒多肽疫苗及其制备方法
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6096863A (en) * 1996-08-23 2000-08-01 Regents Of The University Of Minnesota Self-assembling amphiphiles for construction of peptide secondary structures
DE19638044A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Immunogene Peptide von Maul- und Klauenseuchen-Viren
US6048538A (en) * 1997-10-03 2000-04-11 United Biomedical, Inc. Peptides derived from the non-structural proteins of foot and mouth disease virus as diagnostic reagents
EA003101B1 (ru) 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN100342911C (zh) * 2004-01-13 2007-10-17 厦门大学 A、o型口蹄疫病毒双价dna疫苗及其制备方法
WO2010032140A2 (en) 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
CN107080846A (zh) 2010-07-09 2017-08-22 詹姆斯.特林卡.格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
US10420832B2 (en) 2012-11-16 2019-09-24 United Biomedical, Inc. Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)
KR20170097116A (ko) 2015-01-16 2017-08-25 조에티스 서비시즈 엘엘씨 구제역 백신
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
CN107365367A (zh) * 2017-08-16 2017-11-21 山东省农业科学院奶牛研究中心 A型口蹄疫病毒vp1蛋白抗原表位基因多肽及其应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2022221144A1 (en) * 2021-04-12 2022-10-20 University Of Washington Engineered peptides for αvβ6 integrin binding and related methods of use and synthesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140763A (en) * 1976-09-08 1979-02-20 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for foot and mouth disease
PT73021B (en) * 1980-05-12 1983-10-19 Biogen Nv Process for producing dna sequences of recombinant dna molecules and polipeptides with specificyty on foot mouth disease as viral antigens
EP0068693A3 (en) * 1981-06-16 1983-07-20 Genentech, Inc. Production of foot and mouth disease vaccine from microbially expressed antigens
ZA831854B (en) * 1982-03-26 1984-01-25 Biogen Nv Small peptides with the specificity of foot and mouth disease viral antigens
DE3382459D1 (de) 1982-04-14 1991-12-19 James L Bittle Kuenstliches pikornavirusantigen.

Also Published As

Publication number Publication date
ZA863911B (en) 1988-01-27
AU5821286A (en) 1986-12-11
US4732971A (en) 1988-03-22
ATA141786A (de) 1992-11-15
DE3686095T2 (de) 1993-03-04
HK101692A (en) 1992-12-24
AU595531B2 (en) 1990-04-05
EP0204480A2 (en) 1986-12-10
KR890003944B1 (ko) 1989-10-13
PT82651A (en) 1986-06-01
IL78913A (en) 1991-01-31
AT396248B (de) 1993-07-26
EP0204480B1 (en) 1992-07-22
DK251286D0 (da) 1986-05-29
ES555668A0 (es) 1987-08-16
JPS61282398A (ja) 1986-12-12
IL78913A0 (en) 1986-09-30
PT82651B (pt) 1988-11-30
DK251286A (da) 1986-12-04
EP0204480A3 (en) 1989-02-08
CN86103718A (zh) 1987-02-04
DE3686095D1 (de) 1992-08-27
EG17812A (en) 1990-08-30
GR861406B (en) 1986-09-30
CN1019267B (zh) 1992-12-02
SG94792G (en) 1992-12-04
ES8707739A1 (es) 1987-08-16
SU1662338A3 (ru) 1991-07-07
HUT41050A (en) 1987-03-30
NZ216362A (en) 1989-04-26

Similar Documents

Publication Publication Date Title
KR870000426A (ko) 합성 fmdv 백신용 화합물의 제조방법
Diez et al. Unique amino acid substitutions in the capsid proteins of foot-and-mouth disease virus from a persistent infection in cell culture
Misra et al. Proteins specified by bovine herpesvirus 1 (infectious bovine rhinotracheitis virus)
Grakoui et al. A second hepatitis C virus-encoded proteinase.
Ramig et al. Genome RNAs and polypeptides of reovirus serotypes 1, 2, and 3
Becht Infectious bursal disease virus
Garwes et al. The polypeptide structure of transmissible gastroenteritis virus
Donson et al. The nucleotide sequence of a geminivirus from Digitaria sanguinalis
FI107610B (fi) HCV-fuusioproteiini
Yin et al. Host range mutants of human rhinovirus in which nonstructural proteins are altered
Lonberg-Holm et al. Comparison of in vitro and cell-mediated alteration of a human rhinovirus and its inhibition by sodium dodecyl sulfate
YU48038B (sh) Postupak za dijagnostiku ne-a, ne-v hepatitisa
Emini et al. Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses
Tellinghuisen et al. Nucleic acid-dependent cross-linking of the nucleocapsid protein of Sindbis virus
Romanova et al. Biochemical evidence for intertypic genetic recombination of polioviruses
Duda et al. Bacteriophage HK97 head assembly
Charini et al. Transduction of a human RNA sequence by poliovirus
Bablanian et al. Characterization of the foot-and-mouth disease virus 3C protease expressed in Escherichia coli
Cross et al. Reovirus-specific polypeptides: analysis using discontinuous gel electrophoresis
Macnaughton The polypeptides of human and mouse coronaviruses
Ni et al. Identification of proteins encoded by avian reoviruses and evidence for post-translational modification
Grubman et al. Antigenic comparison of the polypeptides of foot-and-mouth disease virus serotypes and other picornaviruses
Hughes et al. Hypothermia-inducing peptide promotes recovery of vesicular stomatitis virus from persistent animal infections
Burge et al. Conserved peptides in the proteins of vesicular stomatitis virus
Barteling et al. Isolation and characterization of trypsin-resistant O1 variants of foot-and-mouth disease virus

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19921002

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee